Orion Pharma and Pfizer to extend collaboration in Animal Health
The agreement between Orion Pharma and Pfizer concerning development and commercialisation collaboration in the field of sedation and pain management in animal health will provide significant growth opportunities to the net sales of Orion Pharma Animal Health. The agreement will both intensify and expand the already existing strong partnership of the two companies in sedation and pain management. Under previous agreements dating back over many years, Pfizer already has been the marketer for Orion Pharma's animal sedative product family in the USA and most European markets. Under the new agreement, the marketing territory of Pfizer for these products is expanded with major additional markets such as China, Thailand, Middle East and Latin America.
The collaboration of Orion Pharma and Pfizer also encompasses the further development of the Domosedan and Domitor products, the former being used for the sedation of horses and other large animals, the latter being used for dogs and other companion animals. The initial work on these potential new products has been undertaken by Orion Pharma, but the companies will collaborate on the clinical development of the projects.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
